Chicago Equity Partners’s PDL BioPharma, Inc. PDLI Stock Holding History

Chicago Equity Partners’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$34K	Sell	11,940 -170,570	-93%	-$550K	﹤0.01%	642
2019 Q4	$592K	Sell	182,510 -336,805	-65%	-$978K	0.03%	599
2019 Q3	$1.12M	Sell	519,315 -27,172	-5%	-$72.6K	0.05%	460
2019 Q2	$1.72M	Buy	546,487 +442,247	+424%	+$1.43M	0.08%	369
2019 Q1	$388K	Hold	104,240	–	–	0.02%	724
2018 Q4	$302K	Buy	+104,240	New	+$286K	0.01%	731
2018 Q1	–	Sell	-461,100	Closed	-$1.26M	–	851
2017 Q4	$1.26M	Buy	+461,100	New	+$1.42M	0.04%	453
2014 Q4	–	Sell	-20,180	Closed	-$150K	–	510
2014 Q3	$150K	Sell	20,180 -9,670	-32%	-$89.8K	﹤0.01%	435
2014 Q2	$288K	Sell	29,850 -1,525	-5%	-$13.6K	0.01%	373
2014 Q1	$260K	Buy	31,375 +425	+1%	+$3.64K	0.01%	405
2013 Q4	$261K	Buy	+30,950	New	+$261K	0.01%	374

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Chicago Equity Partners's PDLI Position: Q1 2020 in Review

Chicago Equity Partners reduced its PDL BioPharma, Inc. (PDLI) stake by 93% in Q1 2020, selling an estimated $550K and leaving 11,940 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #642.

Chicago Equity Partners first reported a position in PDLI in Q4 2013 and has held it in 11 quarters since. The position peaked at $1.72M in Q2 2019. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

Chicago Equity Partners held 11,940 shares of PDL BioPharma, Inc. worth $34K as of Q1 2020.
Chicago Equity Partners sold 170,570 PDL BioPharma, Inc. shares in Q1 2020, an estimated $550K.
PDL BioPharma, Inc. made up ﹤0.01% of Chicago Equity Partners's portfolio in Q1 2020, its #642 holding.
Chicago Equity Partners first reported a position in PDL BioPharma, Inc. in Q4 2013 and has held it in 11 quarters since.
Chicago Equity Partners's PDL BioPharma, Inc. position peaked at $1.72M in Q2 2019.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.